SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?


To: Knighty Tin who wrote (93961)1/9/2002 9:58:26 AM
From: JHP  Read Replies (1) | Respond to of 132070
 
Study Published in Cardiology Indicates Vasomedical's EECP Therapy Reduces Angina and Improves Quality of Life in Coronary Disease Patients With a History of Heart Failure Benefits Maintained At Six-Months Post-Treatment

WESTBURY, N.Y., Jan 9, 2002 (BW HealthWire) -- Vasomedical Inc. (Nasdaq: VASO)
announced today that the results of a study of 1,957 coronary artery disease
patients, including a cohort of 548 patients with a history of congestive heart
failure (CHF), enrolled in the International EECP Patient Registry (IEPR)
maintained by the University of Pittsburgh Graduate School of Public Health, who
underwent EECP(R) enhanced external counterpulsation therapy were published in
the December 2001 issue of the peer-review journal Cardiology.

The manuscript, entitled "Benefit and Safety of Enhanced External
Counterpulsation in Treating Coronary Artery Disease Patients with a History of
Congestive Heart Failure," revealed that nearly 70% of patients, both with and
without a history of CHF, experienced an improvement in their functional angina
class with fewer anginal attacks and reported an improved quality of life. These
benefits were maintained during a six-month follow-up period. In addition, a
subgroup analysis of patients with a history of CHF and severe left ventricular
dysfunction (i.e., Ejection Fraction less than 35%) revealed that these patients
benefited similarly to those patients with less severe left ventricular
dysfunction after EECP treatment.

Commenting on the data, lead author William E. Lawson, MD, FACC, Professor of
Cardiology and Chief of the Invasive Laboratory at the State University of New
York at Stony Brook, said "My experience indicates that EECP can markedly
improve functionality and exertional symptoms while reducing the chances for
emergency room visits and hospitalizations in many patients suffering from
ischemic cardiomyopathy and low ejection fractions. These data are impressive
despite the fact that the patients with a history of CHF in this study were
older and had a longer and more severe history of coronary artery disease. As
expected in this severely ill group, the patients with a history of CHF did
experience a greater rate of major adverse cardiovascular events six-months post
treatment than the non-CHF group. However, given the improvements in the CHF
group in both functional class and in quality of life, it is possible that these
patients would have a lower rate of major adverse cardiovascular events compared
to the general population of CHF patients with similar severity of diseases.
Ongoing studies, including the randomized, multi-center PEECH(TM) (Prospective
Evaluation of EECP in Congestive Heart Failure) trial, will tell us just how
effective EECP will be as a disease management tool for heart failure patients."

CHF is a disabling condition affecting nearly 5 million Americans and is the
most frequent cause of hospitalization for those over 65 years of age. CHF
occurs when the heart is unable to pump enough blood to meet the body's demands
and therefore fails to empty its chambers sufficiently. When this occurs, blood
accumulates in the chest and lower limbs. There are approximately 550,000 new
cases of CHF reported each year. Once diagnosed, the average survival for CHF
patients is approximately 5 years. CHF is the single biggest drain on the
Medicare system today and remains the most expensive healthcare problem in the
U.S. and other developed countries. The cost to treat CHF patients in the U.S.
is estimated to be in excess of $50 billion annually.

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing
and supporting external counterpulsation systems based on the Company's
proprietary technology currently indicated for use in cases of angina,
cardiogenic shock and acute myocardial infarction. EECP(R) is a registered
trademark for Vasomedical's enhanced external counterpulsation system. This
system is now in use at major medical centers, including the Beth Israel Medical
Center - New York City, Christ Hospital and Medical Center, the Cleveland
Clinic, Johns Hopkins, JFK Medical Center-Atlantis, FL, Mayo Clinic, the Miami
Heart Institute, the Ochsner Foundation Hospital, the Texas Heart Institute, and
University Hospital at UMDNJ/New Jersey Medical School as well as medical
centers affiliated with Columbia University, State University of New York at
Stony Brook, the University of Pittsburgh, the University of California at San
Diego, the University of California at San Francisco, University of Florida at
Gainesville, and the University of Virginia. The Company provides hospitals,
clinics and private practices with EECP(R) equipment, treatment guidance and a
staff training and maintenance program designed to provide optimal patient
outcomes. Additional information is available on the Company's website at
www.vasomedical.com.



To: Knighty Tin who wrote (93961)1/9/2002 11:35:07 AM
From: BSGrinder  Read Replies (2) | Respond to of 132070
 
Mike, the latest Ben Stein:

Sleep More Soundly With Short-Maturity Bonds

By Ben Stein
Special to TheStreet.com
01/09/2002 09:02 AM EST

All righty, now. For the most part, the stock market has continued its strange rise. When I wrote this, the price-to-earnings ratio of the Dow Jones Industrial Average was above 28, higher than at any other time in the postwar era.

It is higher by a factor of more than two, compared with its average in the 1950s, the last time we had such low inflation and such low short-term interest rates. It's far higher than it was in the 1960s, the last time we had such a big growth in productivity -- and a time of an unsustainable bubble.

The P/E for the S&P 500 stands at 41.4, by far the highest on record in the postwar period and about double the P/E of the highest year before 1999, which was 1961, when it hit 21.7. By the way, after the S&P hit a P/E of 21.7 in 1961, it took 30 years for the P/E to get that high again.

The S&P Industrials, not quite as broad an index, sports a P/E of about 53, which is an all-time high, and the Dow Jones Utility Average has a P/E of 46, which is close to an all-time high as well. Of course, as I have so painfully noted, the P/E of the Dow Jones Transportation Average cannot be calculated at all because there's no E with which to calculate it. But let's let that rest for a week and go on to something else.

A Qualified Yes
I get a lot of mail from readers. As long as they don't curse at me or say mean things to me in Yiddish, most of them send friendly and thoughtful notes. Lately, many of my correspondents have been asking if I like bonds in this era. The answer is a resounding, "Yes, but..."

As we all know, I think stocks are so high that returns for the next decade will be small, if not negative. (I'll have much more data on that next week.) But bonds of lengths beyond five years also scare me. It's conceivable that when the recovery comes, demand for lendable funds will rise, the prospect if not the reality of rising prices will be here, and long-term interest rates could skyrocket.

In that context, the most bizarre part of the current slowdown has been the amazing stubbornness of long-term lending rates, surely a prediction by lenders that they expect rates to go up soon -- and sharply.

For example, while the shortest-term rates at banks and brokerages for money have fallen by astounding amounts -- from about 6% on 13-week money one year ago to about 1.71% today -- long-term bond rates have scarcely budged. The Dow 20 bond yield was 7.8% a year ago, and it's about 7.3% now. That is, the yield on short-term money has fallen by 75%, while the yield on long-term loans in investment-grade bonds has fallen by about 6%. (Not 6 percentage points -- 6%.)

If long-term interest rates rise, then long-term bonds will fall in price, possibly sharply. (The price must fall to equilibrate the yield of the old and new bonds.) Thus, some fear about long-term bonds abides in my little heart.

But short-term bonds by definition are close to their payoff. Thus, their price fluctuates only a little compared with long-term bonds. Also, short-term bond funds are constantly buying new bonds, and if interest rates rise, their new bonds will bear higher yields than the old ones and will keep yields fairly current at the short end.

Getting Some Gains
Most interesting is that you can capture most of the interest rate gain in bonds as compared with cash by going out only a couple of years. That is, you can get about 3% on risk-free cash in some bank passbook and/or money market accounts, about 7.3% on very risky long-term bonds and about 5.1% on much-less-risky short-term government bond funds. You get about half of the coupon differential without sacrificing much in the way of principal risk. I have some of this stuff, in the form of the MFS Limited Maturity fund. It's not exciting, but it helps me sleep at night.

I also really like tax-free short-term bond funds. I live in California, where we have very high state income taxes. A 4% tax-free yield for me is very close to an 8% taxable yield, and this is good stuff indeed, especially if the credits are highly rated. I have some American Century California Limited-Term fund, and I like it so far. If something bad happens to it, I will let you know.

I do not foresee that these bond funds can double -- except maybe in a decade or more. In fact, they might double in about 14 years to 18 years. But at this point in my life (I'm 57), I'm much more concerned with not getting hit by another bubble popping than about missing out on a thousand points of the Nasdaq. Gain is a great thing, and capital appreciation is also a great thing. But asset preservation sounds nice, too.

I still have a lot of stocks, but I am getting out of them as a percentage, little by little, and going into safer items. If you have an investment horizon of less than 20 years, you might want to think about whether you can absorb another debacle like the one in 2000-2001 or the worse one from 1966 to the mid-1980s. How would you feel if your investment portfolio fell by one-third and stayed down for 20 years? Then maybe think about bonds of short maturity.

Next week, I'll discuss why the usual stock valuation models, compared with bond valuation models, are deeply screwed up at this point.



To: Knighty Tin who wrote (93961)1/9/2002 11:58:01 AM
From: KENNETH R SANDERS  Read Replies (1) | Respond to of 132070
 
KT' Did your " good will" get written off the books and replaced by "bad won't" ?